Posted by Michael Wonder on 22 Jul 2024
Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for adalimumab-adbm injection, Boehringer’s biosimilar to Humira
18 July 2024 - First biosimilar with an exclusive low cash price on the GoodRx platform.
Boehringer Ingelheim and GoodRx announced today a patient affordability initiative to provide citrate-free adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), at a low cash price available exclusively on GoodRx.
